# US 2021/0171903 A1 · Universal donor stem cells and related methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171903 A1
- Document ID: US20210171903A1
- Status: Published application
- Kind: A1
- Application number: 16/908,618
- Filed: 2020-06-22
- Published: 2021-06-10
- Earliest claimed: 2018-02-15
- Assignees: President and Fellows of Harvard College
- Applicants: President and Fellows of Harvard College
- Inventors: Torsten B. Meissner; Leonardo M.R. Ferreira; Jack L. Strominger; Chad A. Cowan
- Web page: https://patentgrep.com/patent/US20210171903A1

## CPC

- C12N 5/0606: {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696)}
- C07K 14/70503: {Immunoglobulin superfamily}
- C07K 14/70532: {B7 molecules, e.g. CD80, CD86}
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C12N 2510/00: Genetically modified cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed herein are universal donor stem cells and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming the immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor stem cells disclosed herein have modulated expression of one or more MHC-I and MHC-II human leukocyte antigens and one or more tolerogenic factors.

## Claims

### Claim at position 1

-56. (canceled)

### Claim 57

A hypoimmunogenic stem cell comprising three exogenous genes encoding PD-L1, HLA-G, and CD47, respectively, wherein the three exogenous genes are inserted into a safe harbor locus of at least one allele of the hypoimmunogenic stem cell.

### Claim 58 (depends on 57)

The hypoimmunogenic stem cell of claim 57, further comprising reduced expression of HLA-A, HLA-B, HLA-C, and CIITA.

### Claim 59 (depends on 58)

The hypoimmunogenic stem cell of claim 58, wherein the hypoimmunogenic stem cell does not express HLA-A, HLA-B, HLA-C, and CIITA.

### Claim 60 (depends on 57)

The hypoimmunogenic stem cell of claim 57, wherein the hypoimmunogenic stem cell retains differentiation potential.

### Claim 61 (depends on 57)

The hypoimmunogenic stem cell of claim 57, wherein the hypoimmunogenic stem cell elicits a reduced adaptive immune response and a reduced innate immune response in a subject into which the hypoimmunogenic stem cell is transplanted as compared to responses elicited by a wild type stem cell.

### Claim 62 (depends on 57)

The hypoimmunogenic stem cell of claim 57, wherein the hypoimmunogenic stem cell elicits reduced immune responses from T cells, NK cells, and/or macrophages in a subject into which the hypoimmunogenic stem cell is transplanted as compared to responses elicited by a wild type stem cell.

### Claim 63 (depends on 62)

The hypoimmunogenic stem cell of claim 62, wherein the T cells are CD8+ T cells.

### Claim 64 (depends on 57)

The hypoimmunogenic stem cell of claim 57, wherein the safe harbor locus is an AAVS1 locus.

### Claim 65 (depends on 57)

The hypoimmunogenic stem cell of claim 57, wherein the safe harbor locus is a HPRT locus.

### Claim 66

A nucleic acid molecule comprising:
i) an expression cassette comprising:
a) a first nucleic acid sequence encoding PD-L1,
b) a second nucleic acid sequence encoding HLA-G, and
c) a third nucleic acid sequence encoding CD47,
ii) a promoter that induces overexpression of PD-L1, HLA-G, and CD47, and
iii) a first arm sequence and a second arm sequence, wherein the first arm sequence is located upstream of the expression cassette and the promoter and the second arm sequence is located downstream of the expression cassette and the promoter, and wherein the arm sequences are homologous to a safe harbor locus of a target stem cell.

### Claim 67 (depends on 66)

The nucleic acid molecule of claim 66, wherein the safe harbor locus is an AAVS1 locus.

### Claim 68 (depends on 66)

The nucleic acid molecule of claim 66, wherein the safe harbor locus is a HPRT locus.

### Claim 69 (depends on 66)

The nucleic acid molecule of claim 66, wherein the promoter is a CAGGS promoter.

### Claim 70

A hypoimmunogenic stem cell comprising two exogenous genes encoding PD-L1 and CD47, respectively, wherein the two exogenous genes are inserted into a safe harbor locus of at least one allele of the hypoimmunogenic stem cell.

### Claim 71 (depends on 70)

The hypoimmunogenic stem cell of claim 70, further comprising reduced expression of HLA-A, HLA-B, HLA-C, and CIITA.

### Claim 72 (depends on 71)

The hypoimmunogenic stem cell of claim 71, wherein the hypoimmunogenic stem cell comprises no expression of HLA-A, HLA-B, HLA-C, and CIITA.

### Claim 73 (depends on 70)

The hypoimmunogenic stem cell of claim 70, wherein the hypoimmunogenic stem cell retains differentiation potential.

### Claim 74 (depends on 70)

The hypoimmunogenic stem cell of claim 70, wherein the hypoimmunogenic stem cell elicits reduced immune responses from T cells and/or macrophages in a subject into which the hypoimmunogenic stem cell is transplanted as compared to immune responses elicited by a wild type stem cell.

### Claim 75 (depends on 74)

The hypoimmunogenic stem cell of claim 74, wherein the T cells are CD8+ T cells.

### Claim 76 (depends on 70)

The hypoimmunogenic stem cell of claim 70, wherein the safe harbor locus is an AAVS1 locus.

### Claim 77 (depends on 70)

The hypoimmunogenic stem cell of claim 70, wherein the safe harbor locus is a HPRT locus.

### Claim 78

A nucleic acid molecule comprising:
i) an expression cassette comprising:
a) a first nucleic acid sequence encoding PD-L1, and
b) a second nucleic acid sequence encoding CD47,
ii) a promoter that induces overexpression of PD-L1 and CD47, and
iii) a first arm sequence and a second arm sequence, wherein the first arm sequence is located upstream of the expression cassette and the promoter and the second arm sequence is located downstream of the expression cassette and the promoter, and wherein the arm sequences homologous to a safe harbor locus of a target stem cell.

### Claim 79 (depends on 78)

The nucleic acid molecule of claim 78, wherein the safe harbor locus is an AAVS1 locus.

### Claim 80 (depends on 78)

The nucleic acid molecule of claim 78, wherein the safe harbor locus is a HPRT locus.

### Claim 81 (depends on 78)

The nucleic acid molecule of claim 78, wherein the promoter is a CAGGS promoter.
